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Abstract. In February 2014, the Malaria Elimination Working Group, in partnership with the Peruvian Ministry of
Health (MoH), hosted its first international conference on malaria elimination in Iquitos, Peru. The 2-day meeting gath-
ered 85 malaria experts, including 18 international panelists, 23 stakeholders from different malaria-endemic regions
of Peru, and 11 MoH authorities. The main outcome was consensus that implementing a malaria elimination project in
the Amazon region is achievable, but would require: 1) a comprehensive strategic plan, 2) the altering of current pro-
grammatic guidelines from control toward elimination by including symptomatic as well as asymptomatic individuals for
antimalarial therapy and transmission-blocking interventions, and 3) the prioritization of community-based active case
detection with proper rapid diagnostic tests to interrupt transmission. Elimination efforts must involve key stakeholders
and experts at every level of government and include integrated research activities to evaluate, implement, and tailor sus-
tainable interventions appropriate to the region.
INTRODUCTION
Malaria continues to represent a major public health threat,
exerting a significant disease burden worldwide.1 Although
disease burden is highest in sub-Saharan Africa, malaria also
causes a significant burden in other regions such as south and
southeast Asia, Oceania, and Central and South America.2,3
Malaria elimination efforts are primarily focused on African
countries and particularly on Plasmodium falciparum due to
the mortality it causes in the poorest countries in the African
region.4 This situation has resulted in an increasing gap in
the collective knowledge about how to control this disease
in regions where the malaria cases are predominantly due to
Plasmodium vivax,2 the most widely distributed Plasmodium
species that causes malaria.5 Plasmodium vivax is biologically
and epidemiologically different from P. falciparum and it
is not, therefore, appropriate to assume that interventions
developed for falciparum malaria are directly transferable to
P. vivax.6,7 With 2.8 billion people at risk of acquiring P. vivax
malaria,5 the question as to how to best interrupt its trans-
mission and achieve elimination in regions where P. vivax is
highly predominant has received little focused attention. More
recent research has demonstrated its potential to be an indi-
rect cause of death,8 to adversely impact child growth,9 to
cause severe and frequent illness,10 and to demonstrate a
reduced response to chloroquine.11,12 Given this, malaria
researchers have been working to address key knowledge
gaps, characterize the pattern of transmission of malaria, and
identify high-risk groups that must be targeted to interrupt
transmission, as well as to understand the patterns of human
migration in vivax-predominant regions.
In the last two decades, research conducted in Peru has
significantly contributed to the expansion of knowledge about
malaria, particularly in the fields of vivax malaria epide-
miology, diagnostics, therapeutics, and vector biology. The
contributions include key epidemiological aspects of vivax
transmission such as occupation-related travel,13 high P. vivax
parasite genetic diversity,14 clustering and microepidemiology
of infection,15,16 the human asymptomatic malaria reservoir,17–19
some sociodemographic20 and microgeographical21 charac-
teristics of the sustainability of malaria transmission, and the
serious consequences of severe vivax malaria.22 In addition,
with the discovery of P. falciparum strains lacking the histidine-
rich protein-2 (PfHRP2)23 and the spread of such strains within
Peru, researchers were able to assess and identify better
alternatives for rapid diagnostic tests (RDTs) specific for the
regional strains.24 Peru has contributed to clinical research in
therapeutics and antimalarial resistance, including a clini-
cal trial of tafenoquine,25 and new data on how to improve
the utilization of conventional antimalarials within Peru,
including mefloquine and artesunate,26–28 primaquine,29,30 and
dihydroartemisinin–piperaquine.31 Furthermore, similar research
has contributed to the further understanding of the dynamics
of antimalarial resistance, particularly in regards to the resis-
tance to chloroquine,32 sulfadoxine–pyrimethamine,33–36 and
mefloquine.34 Finally, research from Peru has contributed to
the study of vector biology and ecology, particularly on the
behavior37–40 and population structure41–43 ofAnopheles darlingi
and Anopheles benarrochi, the two main malaria vectors in the
Amazon basin. We anticipate that as a result of the recently
developed model of An. darlingi infections,44–46 the impor-
tance of these contributions will only continue to increase.
All of these scientific contributions were possible mainly
because of a highly productive and internationally collabora-
tive malaria research network that has been established in the
Peruvian Amazon and north coast.
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SWITCHING FROM CONTROL TOWARD
ELIMINATION IN PERU: AWORK IN PROGRESS
In the past, Peru achieved a level of control that twice
suggested that malaria elimination might be feasible (Figure 1).
First, after peaking with over 90,000 cases in 1944, the malaria
burden fell to below 1,500 cases (98% reduction) in 1965, with
∼1–2 cases per 10,000 inhabitants reported for approximately
two decades.47 Such success was assumed to be related to the
combination of dichlorodiphenyltrichloroethane (DDT) use for
vector control, epidemiology and laboratory capacity building,
and the shift of focus from case management to transmission
control within the National Malaria Service, an effort that was
initially sponsored by the Rockefeller Foundation and later
by the Inter-American Public Health Service and the United
Nations Children’s Emergency Fund.48 DDT use was halted
initially in Loreto in 1988 and then stopped across the coun-
try, a policy change that may explain why over the next
decade,49 malaria increased 4-fold in Peru and 50-fold in
Loreto.47 After peaking in 1998 with 250,000 cases, the
malaria case number dropped to 25,300 cases in 2011, a 90%
reduction. The Peruvian authorities quickly responded to
this malaria reemergence by updating the national malaria
guidelines, introducing mefloquine–artesunate (artemisinin-
based combination therapies [ACTs]) as the first line of treat-
ment of P. falciparum malaria.50,51 From 2006 to 2011, Peru
implemented the Project of Malaria Control within the Bor-
ders of the Andean Region sponsored by the Global Fund.
This program implemented a variety of interventions including
distributing over 250,000 long-lasting insecticide-impregnated
nets (LLIN), using RDTs in remote communities, building
capacity for microscopy-based diagnosis, and training com-
munity health workers in Loreto only.52 We have not con-
sidered whether LLINs function effectively in the Amazon,
both because of patterns of mosquito feeding and cultural
factors. Moreover, previous observations indicate that the
use of transparent LLINs was low, mainly because they failed
to provide privacy, shelter, and a sense of security for young
children as offered by traditional mosquito nets.53,54 Assess-
ment of peak biting times vis-a-vis sleeping/LLIN usage times
remain to be assessed.
The number of falciparum and vivax malaria cases increased
alarmingly from 2,238 to 10,243 and from 9,208 to 52,323 cases,
respectively, from 2010 to 2014.55 The 2012 flooding and
the recent political instability that affected the region are
likely contributors to a resurgence of cases. The Amazonian
Department of Loreto continues to report the vast majority
of malaria cases in Peru at 94%.55 In Loreto, malaria is
largely seasonal, disproportionally affects adult men (loggers,
fishermen, farmers, and other laborers that live in higher
transmission regions or travel often13,20), and is dispersed
across riverine communities (Figure 2).56 The epidemiology
of malaria in other endemic Amazonian regions such as
San Martin and Ucayali vary slightly compared with Loreto.
However, in other regions such as on the north coast (Tumbes,
Piura, Lambayeque, and La Libertad), the epidemiology
is considerably different, occurring with epidemic and spo-
radic patterns probably related to stochastic factors such as
reintroductions.57 On the north coast, the predominant malaria
vector is Anopheles albimanus58 and P. falciparum malaria has
rarely been reported in this region since 2010. Malaria is
highly concentrated within periurban communities,59 and
across the region, the annual number of malaria cases per
1,000 inhabitants has dropped below 0.01 since 2013.55 Cer-
tainly, the malaria vectors do not stop at any border, neither
national nor international, so given that the reintroduction
of malaria is likely to occur across the borders, there is a
strong need for active program alliances that address both
national and transnational issues. Programs such as the Amazon
Malaria Initiative and the Peru-Brazil International Centers
of Excellence for Malaria Research are contributing to build
the necessary knowledge to eliminate malaria in the Peruvian
Amazon but more needs to be done.
REVIEWING THE AGENDA OF MALARIA
ELIMINATION IN PERU: CONFERENCE
ORGANIZATION AND AIMS
Early in 2014, a conference was held in the city of Iquitos,
the capital of Loreto, on February 16–17 to review the agenda
of malaria elimination in Peru. The main objective was to
engage the research community and decision makers in a
collaborative effort to define the critical knowledge gaps and
policy requirements to achieve and sustain malaria elimination
in Peru. In attendance were representatives from regional
organizations, national organizations, the Ministry of Health,
and international participants. In this conference, 25 different
organizations were represented (Table 1). Local experts and
stakeholders were well represented in the conference. Of
the 85 conference participants, 53 were Peruvian, including
34 researchers and authorities from the Loreto region, and
32 were international, most with long track records working
on national public health priorities in Peru. Four of the six
FIGURE 1. Historical trend of reported malaria incidence in Peru:
1939–2014. Annual Parasite Index (total of subjects that tested smear
positive to malaria per 1,000 inhabitants) in Peru since 1939 to date.
Here the red dashed line represents the threshold of one case per
1,000 inhabitants, which in the case of Peru has been overcome only
twice: in the late 1960s and in the early 2010s. During this whole
period, several important interventions were introduced in the coun-
try. In 1944, the Rockefeller Foundation sponsored the introduction
of dichlorodiphenyltrichloroethane (DDT), but after several years of
continuous spraying and malaria-burden decline, such funding ceased
in 1970. In 1988, DDT use was halted first in Loreto and later in the
rest of the country, mainly because of the emergence of DDT resis-
tance and lack of funding. In 1996, sulphadoxine–pyrimethamine (SP)
replaced chloroquine (CQ) as the first-line treatment of uncompli-
cated falciparum malaria, but after several clinical trials, Peru decided
to adopt artemisinin-based combination therapies (ACTs) to replace
SP in 2001, remaining as such to date.
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board members were Peruvian and 19 of the 30 consulting
committee members were Peruvian.
To meet this objective, the conference integrated two formats
for soliciting expert input and achieving consensus. On the first
day, individual experts gave presentations that reviewed: past
malaria control and elimination efforts; current opportunities
and challenges for malaria elimination in the Americas; the
potential role of transmission-blocking vaccines, seroepidemiology,
FIGURE 2. Geographical distribution of reported malaria cases in Loreto, 2013. Distribution of malaria across communities in the Loreto
Department. Each bubble represents a reporting community in the national surveillance system. The size of the bubble represents the size of the
population of each community, whereas the color represents the Annual Parasite Index (total of subjects that tested smear positive to malaria per
1,000 inhabitants) in the year 2013. The blue lines represent the tributaries of the Amazon river and the dashed line indicates the district bound-
aries. In 2013, 24% (12/51) of the districts represented over 80% of the total number of malaria cases reported in the Loreto region, whereas 4%
of the communities contributed to over 30% of the total number of malaria cases in the same year.
TABLE 1
Partners and collaborating organizations
Acronym Organization name
BMGF Bill & Melinda Gates Foundation
CGHD-CWRU Case Western Reserve University
CSRC Caucaseco Scientific Research Center
DGE Dirección General de Epidemiología (General Epidemiology Directorate)
DIRESA Junín Dirección Regional de Salud de Junín (Junin Regional Health Directorate)
DIRESA Loreto Dirección Regional de Salud de Loreto (Loreto Regional Health Directorate)
DIRESA Madre de Dios Dirección Regional de Salud de Madre de Dios (Madre de Dios Regional Health Directorate)
DIRESA Piura Dirección Regional de Salud de Piura (Piura Regional Health Directorate)
DIRESA San Martín Dirección Regional de Salud de San Martín (San Martin’s Regional Health Directorate)
DIRESATumbes Dirección Regional de Salud de Tumbes (Tumbes’ Regional Health Directorate)
ESNEM Estrategia Sanitaria Nacional de Prevención y Control de Enfermedades Metaxenicas
(National Sanitary Strategy for the Prevention and Control of Vector Borne Diseases)
GRL Gobierno Regional de Loreto (Loreto Regional Government)
ICEMR Peru–Brazil International Center of Excellence in Malaria Research
INS Instituto Nacional de Salud (National Health Institute)
JHBSPH Johns Hopkins Bloomberg School of Public Health
MINSA Ministerio de Salud (Ministry of Health)
NAMRU-6 U.S. Naval Medical Research Unit No. 6
PAHO Pan American Health Organization
PATH Program for Appropriate Technology in Health
PRISMA Proyectos de Informática, Salud, Medicina, y Agricultura
UCSD University of California, San Diego
UNAP Universidad Nacional de la Amazonía Peruana, Loreto (National University of the Peruvian Amazon)
UPCH Universidad Peruana Cayetano Heredia (Cayetano Heredia Peruvian University)
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and diagnostic technologies in malaria elimination; and the
role of social and behavioral considerations in malaria diag-
nostics and interventions. The discussions included the micro-
epidemiology of malaria, various strategies and challenges of
malaria elimination in this region, and the benefits and practi-
calities of a demonstrative elimination project. On the second
day, we convened the first meeting of the newly formed
Malaria Elimination Working Group, a multiorganizational,
multidisciplinary group of malaria researchers convened to
support the agenda of malaria elimination in the Amazon
region, with a particular focus in the Peruvian Amazon.
The group’s goal is to promote innovative solutions to the
scientific, technical, operational, financial, and programmatic
challenges that decision makers will need to address when pur-
suing a malaria elimination initiative. The second day’s agenda
comprised four different round table discussions led by experts
to achieve consensus on several different aspects that were con-
sidered highly relevant to malaria elimination. These included:
1) feasibility and project sites, 2) project aims and outcomes,
3) diagnostics, interventions, and methods, and 4) the gaps
and priorities in the future research agenda. During the closing
discussion of the conference, the moderators of each group
presented the outcomes of their discussions.
FEASIBILITY OFA MALARIA ELIMINATION
PROJECT IN THE PERUVIAN AMAZON
The group concluded that implementing a malaria elimina-
tion project in the Peruvian Amazon is feasible, although its
success will require a clear financial and political commit-
ment from the Peruvian government. For this purpose, it will
be crucial to establish a comprehensive regional strategic
plan to guide this project. Peruvian public health activities
should continue to focus on basic prevention and control and
to introduce new tools and new strategies as they are devel-
oped. The implemented measures must be integrated, cultur-
ally appropriate, and sustainable in terms of both financing
and political support. The incorporation of other regional
and local authorities (such as provincial governors and local
leaders at the city and village levels) will also be important.
A critical aspect of the strategy will be the identification
of asymptomatic parasitemic individuals, who are important
reservoirs for continuing transmission, and monitoring how
subsequent interventions affect this population’s potential
for maintaining local malaria transmission. Targeted parasite
elimination strategies that are appropriate to the region must
be used to overcome the limitations of passive case detection
and the difficulties in providing proper coverage to the iso-
lated hard-to-reach populations (either remote communities
or migratory subpopulations such as loggers and gold miners).
Several criteria should be considered in the selection of study
sites: they should have a large population with low annual
parasite index (API < 1) and cultural and political accessi-
bility. The setting must allow for the incorporation of new
validated tools to augment standard control measures. In
addition, the study sites must be close to each other, poten-
tially within the same river basin, and the regions surrounding
the study area must have control measures in place to pre-
vent reintroduction. Finally, considering the ethical implica-
tions, it must be determined whether these interventions are
in the public health interest of the study sites, and if suc-
cessful, these interventions should be scaled up to include
neighboring communities.
AIMS AND OUTCOMES OF A MALARIA
ELIMINATION PROJECT
The group discussed various outcomes that might be useful
in assessing the impact of a malaria elimination strategy in the
Peruvian Amazon. Many indicators were evaluated but only a
few were recommended by the group to be considered rele-
vant to measure the impact of a malaria elimination project.
These included the following: burden of disease, API, posi-
tivity index, incidence rate, seroprevalence, population struc-
ture of the vector species, human biting rate, sporozoite
index, and vector density. Furthermore, the group stressed the
relevance of adapting or developing some process indicators.
These indicators should at least allow a proper measurement
of the project coverage, community responsiveness, capacity
building, as well as the actions to convert the project inputs
into specific human behavior changes. Consensus could not
be reached regarding a reasonable time frame within which
malaria elimination could be achieved in the study sites, pri-
marily because of uncertainties of funding and variations on
approaches. However, the group agreed on several themes
that will be essential when considering malaria elimination
as the ultimate goal. These include an integrated strategy with
properly financed, independent, and dedicated resources and
the subsequent integration of the proposed diagnostic and
intervention measures into the health system. Also, it will be
essential to improve logistic communication and program-
matic monitoring activities among involved interdisciplinary
and intersectoral groups. In the scope of a malaria elimination
project, there was a strong agreement that it would be critical
to involve public health and political authorities at the highest
political level to achieve programmatic stability.
KEYASPECTS OF DIAGNOSTICS, INTERVENTIONS,
AND THEIR IMPLEMENTATION IN THE
PERUVIAN AMAZON
Participants in this roundtable carried out a lively discus-
sion on the need for improving current regional diagnostic
platforms with more sensitive but portable diagnostics, par-
ticularly for targeting rural communities and hard-to-reach
high-risk populations such as loggers, farmers, and fishermen.
In this discussion, the group emphasized that it will be criti-
cal to introduce sufficiently sensitive RDTs that are appro-
priate for the Peruvian context as well as to address the
administrative and logistical barriers that might prevent a
regular and continuous supply. This is particularly true for
both P. falciparum and P. vivax, given the high prevalence
of PfHRP2,23 its multiple genetic origins,24 and the consid-
erable variability in the diagnostic accuracy of some of the
pan-lactate dehydrogenase–detecting RDTs in the Peruvian
Amazon.60 In addition, its implementation should follow
locally adapted guidelines. The group recommended that
interventions should be implemented as an integrated pack-
age, accounting for the local sociocultural barriers to clas-
sical interventions such as bed nets and indoor residual
spraying and placing interventions into a local context to
maximize impact. It will be essential to monitor and evalu-
ate programs and interventions from a research perspective
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(e.g., surveillance for emerging drug resistance). Consensus
was reached on the need to have a mechanism to maintain
updated Peruvian national malaria clinical guidelines; for
example, taking into account new data indicating the need
for ACT plus primaquine to effectively treat and block trans-
mission of P. falciparum malaria. Moreover, to shift the goal
from control toward elimination, there is a need to target the
malaria parasite reservoir (treating both asymptomatic and
symptomatic infections) instead of just the malaria disease
burden (malaria symptomatic infections only). Finally, for the
initiative to be successful, the group agreed that steps must
be taken to assure a continual supply of the RDTs and anti-
malarial drugs proposed for use in the region.
GAPS AND PRIORITIES IN THE FUTURE
RESEARCH AGENDA
Several recommendations were made regarding key ele-
ments of the future research agenda (Table 2). These include
that research and evaluation of a malaria elimination project
should have clear and achievable milestones, progress from
simple to more complex interventions, and involve all the
different stakeholders (national and local government, aca-
demia, and nongovernmental organizations). Its implemen-
tation should be carefully planned to overcome operational
challenges by identifying and integrating key providers within
the project. Mobile and internet coverage is currently restricted
mainly to periurban Iquitos, which represents a major bar-
rier for the development of public health interventions. The
implementation and operational research should incorpo-
rate social science and account for the social determinants
of malaria to find culturally acceptable ways to intervene.
Integrated approaches should be considered as means to
strengthen the impact of any malaria elimination project, par-
ticularly in the most remote communities, as well as to sustain
the political will and support. Importantly, the focus of elimi-
nation efforts must be on the most important reservoirs
of maintaining malaria endemicity and transmission rather
than solely on symptomatic individuals. Such an approach
will require better tools to efficiently identify carriers (serology
and molecular assays complementary to RDTs and micros-
copy). Research on vector behavior, including monitoring and
surveillance for insecticide resistance, as well as research on
the local customs and preferences for bed net usage are cru-
cial for understanding and deploying effective and widely used
vector control interventions. With regards to therapeutics,
there is a need for improved policies to establish a stream-
lined process to incorporate new drugs into the Peruvian
national formulary.
CONCLUSIONS AND FUTURE DIRECTIONS
Several key conclusions and points of consensus arose from
this meeting. The most important one is that malaria elimina-
tion in the Peruvian Amazon can be achievable and should
be a national and international priority. A comprehensive
regional strategic plan needs to be developed that addresses
key technical, operational, and economical considerations
such as the ones recommended by the World Health Orga-
nization. It was strongly recommended to first pilot such
a strategy in suitable sites in the region to establish efficacy
and acceptability. When such a strategy is implemented, it
will be important to monitor and evaluate progress through
a variety of metrics and to set intermediate goals on the path
to regional elimination. Targeted parasite elimination strate-
gies that are appropriate to the region must be used, stress-
ing active case detection using sufficiently sensitive and
effective RDTs and species-specific treatment of the asymp-
tomatic reservoir. This is particularly important in the case
of P. falciparum malaria, which must be treated with ACT
and primaquine to interrupt transmission. The strategy must
facilitate the communication between key stakeholders from
the region and political support at all levels of government,
and the program should be incorporated into established
health-care systems to improve acceptability and sustainability.
The progression of such a strategy should be flexible to allow
new knowledge of the social determinants of malaria, the cul-
tural acceptability of key interventions, and novel tests and
treatments to be incorporated throughout the effort. An
agreement on the relevance of pursuing malaria elimination as
a goal was reached during the conference, and the necessary
components and characteristics of this effort were described.
Moving forward, further details should be elaborated as com-
mitments from a critical mass of stakeholders are obtained.
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2. Study sites for new control measures should have large populations, low transmission, and be accessible but resistant to contamination of effect.
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